Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Forest Laboratories is set to launch Daliresp (roflumilast) in pharmacies across the US by mid-June.
Subscribe to our email newsletter
Daliresp is a selective PDE4 inhibitor, indicated as a treatment for reducing the risk of chronic obstructive pulmonary disease (COPD) exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.
Forest Labs has received the US Food and Drug Adminstration’s (FDA) approval for Daliresp on 1 March 2011.
The drug has showed efficacy and safety profile when evaluated in eight clinical studies involving 9,394 adult patients.
Earlier, Forest Labs has got license for Daliresp in the US, under an agreement signed with Nycomed.